HORMONE TREATMENT PROMOTES CASTRATION-RESISTANT PHENOTYPE BY INCREASING PI3K/AKT ACTIVITY IN PROSTATE CANCER MODELS. PRECLINICAL DATA ON COMBINED PHOSPHATIDYLINOSITOL-3-KINASE/MTOR INHIBITION WITH ENDOCRINE THERAPY FOR ANDROGEN RECEPTOR-POSITIVE PROSTATE CANCER CELLS